Brenna C. Carey, MS, PhD
- Member, Translational Pulmonary Center
- Member, Division of Pulmonary Biology
- Assistant Professor, UC Department of Pediatrics
About
MS: Pharmaceutical Sciences with Specialization in Drug Development, University of Cincinnati, College of Pharmacy, Cincinnati, OH, 2010
PhD: Molecular and Developmental Biology, University of Cincinnati, College of Medicine, Cincinnati, OH, 2003
BS: Biology, John Carroll University, University Heights, OH, 1998
Post-doctoral Research Fellow: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2008
Interests
Regulations, management, and coordination of clinical research trials in rare lung diseases, specifically pulmonary alveolar proteinosis (PAP); pathogenesis of PAP; developing and validating clinical research tests to diagnose PAP; evaluating several therapeutic options for individuals with PAP; translational pulmonary science; rare lung disease clinical research diagnostic testing; diagnosis of individuals with hereditary or autoimmune PAP clinical trials; National PAP Registry; inhaled GM-CSF treatment for individuals with autoimmune PAP and hereditary PAP; safety and efficacy of Pioglitazone for autoimmune PAP patients
Research Areas
Publications
Distinct cytokine and chemokine alterations in bronchoalveolar fluid from patients with systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD). Arthritis Research & Therapy. 2026.
Pulmonary Alveolar Proteinosis in Greece-Türkiye-Cyprus: Answers in a Real-Life Comparison. Respirology. 2026.
B95-10 A First-in-human Study of Pulmonary Macrophage Transplantation Therapy of Hereditary Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine. 2026; 212(Supplement_2):aamag286.181.
B28-23 Gm-csf Signaling Deficiency Causes Marked Pulmonary Lymphocytosis Due to Alveolar Macrophage-mediated Recruitment, Altered Lymphoid-myeloid Lineage Commitment, and Local Proliferation. American Journal of Respiratory and Critical Care Medicine. 2026; 212(Supplement_1):aamag162.1143.
B76-04 Alpha-1 Knockout Mice Have Increased Lung Inflammatory Cytokines That Correlate With Protease Activities. American Journal of Respiratory and Critical Care Medicine. 2026; 212(Supplement_1):aamag162.1856.
C39-09 A Practical Tool for Measuring the Severity of Lung Disease in Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine. 2026; 212(Supplement_1):aamag162.2658.
C104-15 Diagnosis and Treatment of Autoimmune Pulmonary Alveolar Proteinosis: Results From the US National PAP Registry. American Journal of Respiratory and Critical Care Medicine. 2026; 212(Supplement_1):aamag162.2829.
DEVELOPMENT OF A DRIED SERUM ASSAY FOR THE DETECTION OF GM-CSF ANTIBODIES TO AID IN THE DIAGNOSIS OF AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) Chest. 2025; 168(4):a3757.
Pharmacokinetics and pharmacodynamics of inhaled molgramostim in healthy people. BMJ Open Respiratory Research. 2025; 12(1).
Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis. New England Journal of Medicine. 2025; 393(8):764-773.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
